Syndax Pharmaceuticals Inc <SNDX.OQ> expected to post a loss of $1.02 a share - Earnings Preview
Syndax Pharmaceuticals Inc SNDX.OQ SNDX.O is expected to show a rise in quarterly revenue when it reports results on August 4 for the period ending June 30 2025
The New York City-based company is expected to report a 666.4% increase in revenue to $26.825 million from $3.5 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
LSEG's mean analyst estimate for Syndax Pharmaceuticals Inc is for a loss of $1.02 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc is $33.50, about 70.4% above its last closing price of $9.92
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -1.20 | -1.33 | -0.98 | Beat | 26.4 |
Dec. 31 2025 | -0.42 | -0.23 | -1.10 | Missed | -380 |
Sep. 30 2024 | -1.14 | -1.11 | -0.98 | Beat | 11.9 |
Jun. 30 2024 | -0.91 | -0.91 | -0.80 | Beat | 12.5 |
Mar. 31 2024 | -0.96 | -0.98 | -0.85 | Beat | 13.1 |
Dec. 31 2023 | -0.97 | -0.99 | -1.00 | Missed | -0.6 |
Sep. 30 2023 | -0.80 | -0.80 | -0.73 | Beat | 8.2 |
Jun. 30 2023 | -0.73 | -0.73 | -0.64 | Beat | 12.6 |
This summary was machine generated August 1 at 21:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
